STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life

STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life

Abstract Background Asthma patients with obesity often have a high disease burden, despite the use of high-dose inhaled corticosteroids (ICS). In contrast to asthmatics with normal weight, the efficacy of ICS in patients with obesity and asthma is often relatively low. Meanwhile, patients do suffer...

Full description

Bibliographic Details
Main Authors: Jan A. Witte, Gert-Jan Braunstahl, Wouter J. B. Blox, Susan C. van ’t Westeinde, Johannes C. C. M. in ’t Veen, Jasper H. Kappen, Elisabeth F. C. van Rossum
Format: Article
Language:English
Published: BMC 2022-02-01
Series:BMC Pulmonary Medicine
Subjects:
Asthma
Obesity
T2-low
Corticosteroids
ICS tapering
RCT
Online Access:https://doi.org/10.1186/s12890-022-01843-0

Internet

https://doi.org/10.1186/s12890-022-01843-0

Similar Items